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Abstract
Background: Carboranes (dicarba-closo-dodecaboranes) are a
class of carbon-containing polyhedral boron-cluster compounds
having remarkable thermal stability and exceptional hydrophobi-
city. Applications of the unique structural and chemical properties
offered by icosahedral carboranes in boron neutron capture
therapy have received increasing attention over the past 30 years.
However, these features of carboranes may allow another
application as a hydrophobic pharmacophore in biologically
active molecules that interact hydrophobically with receptors.
Results : We have designed candidate estrogen-receptor-binding
compounds having carborane as a hydrophobic skeletal structure
and synthesized them. The most potent compound bearing a
carborane cage exhibited activity at least 10-fold greater than that
of 17L-estradiol in the luciferase reporter gene assay. Estrogen
receptor-K-binding data for the compound were consistent with
the results of the luciferase reporter gene assay. The compound
also showed potent in vivo effects on the recovery of uterine
weight and bone loss in ovariectomized mice.
Conclusion: Further development of the potent carborane-
containing estrogenic agonists described here, having a new
skeletal structure and unique characteristics, should yield novel
therapeutic agents, especially selective estrogen receptor modula-
tors. Furthermore, the suitability of the spherical carborane cage
for binding to the cavity of the estrogen receptor-K ligand-binding
domain should provide a basis for a similar approach to
developing novel ligands for other steroid receptors. ß 2001
Elsevier Science Ltd. All rights reserved.
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1. Introduction
The icosahedral carboranes (dicarba-closo-dodecabo-
ranes), which were ¢rst synthesized in the 1960s, have un-
usual properties, such as (1) high boron content, (2) re-
markable thermal and chemical stability, (3) a
hydrophobic surface, and (4) a spherical geometry [1].
The carboranes were utilized in medicinal chemistry in
the ¢eld of boron neutron capture therapy (BNCT) for
incorporation of large numbers of boron atoms into tu-
mor cells. Since the early applications of simple boron-
containing compounds for BNCT, various compounds
have been synthesized by adding carborane units to amino
acids, nucleic acids, porphyrins, DNA binders and carbo-
rane-containing antibodies [2,3]. Among the properties of
carboranes, the high boron content and chemical stability
are useful for BNCT. However, their highly hydrophobic
character prevents the incorporation of these molecules
into tumor cells. Therefore, derivatization of carborane-
containing molecules has been conducted to obtain water
solubility [4]. On the other hand, from the standpoint of
receptor^ligand complexation, the exceptional hydropho-
bic character of carboranes [5,6] may allow their use as a
hydrophobic pharmacophore in biologically active mole-
cules. This concept has been realized by the synthesis of
several biologically active peptides, in which phenylalanine
residues were replaced with (o-carboranyl)alanine [7^10].
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However, little attention has been paid to the possible use
of carborane as a hydrophobic skeletal structure, in the
¢eld of drug design. We have been engaged in the design
and synthesis of new nuclear receptor ligands [11,12] and
signal transduction modulators [13,14], and have recog-
nized the importance of hydrophobic interaction in recep-
tor^ligand complexation. The di¡erence of binding con-
stants between a ligand having a suitable hydrophobic
group and a ligand without such a group sometimes
reaches 100V10000 times. To evaluate the utility of icosa-
hedral carborane as a hydrophobic component for drug
design [15^17], we focused on the design and synthesis of
estrogen agonists bearing a carborane cage as a hydro-
phobic skeletal structure [18].
The steroid hormone estrogen in£uences the growth,
di¡erentiation, and functioning of many target tissues. Es-
trogens play an important role in the female and male
reproductive systems, and also in bone maintenance, in
the central nervous system and in the cardiovascular sys-
tem. The ¢rst step in the appearance of these activities is
mediated by the binding of hormonal ligands to the estro-
gen receptors (ER) K [19] and L [20]. The hormone-bound
ER undergoes a conformational change, allowing the re-
ceptor to dimerize. The dimer functions as a transcription
factor that mediates biological response by binding to spe-
ci¢c promoter elements of DNA to initiate gene transcrip-
tion. Compounds that either induce or inhibit cellular es-
trogen responses have potential value as biochemical tools
and candidates for drug development. In this article, we
describe the synthesis and biological evaluation of novel
carborane-containing estrogenic agonists, which are more
potent than 17L-estradiol.
2. Results
2.1. Ligand design
Since the discovery of the non-steroidal estrogen dieth-
ylstilbestrol [21], many stilbenes, triarylethylenes and other
aromatic compounds have been synthesized and shown to
possess estrogenic activity. Many estrogen agonists and
antagonists [22] have been developed as agents for regu-
lating fertility, preventing and controlling hormone-re-
sponsive breast cancer, and post-menopausal hormone re-
placement. Estrogenic activity has been found in a large
range of structural prototypes, including non-steroidal
compounds isolated from plants, such as £avonoids [23].
On the other hand, the health risks of the estrogenic com-
pounds that are either present in the environment or used
as chemicals have become of interest in recent years [24].
One of the reasons for the estrogenic activity of such a
wide variety of organic chemicals appears to be that ER
binding is primarily the result of interaction between the
receptor and a phenolic residue. Furthermore, the estro-
genic activity is known to depend on the shape of the alkyl
substituent in simple phenols having a bulky alkyl group
at the 4-position. Therefore, high binding a⁄nity for ER
and the appearance of substantial estrogenic activity re-
quire an appropriate hydrophobic group adjacent to the
phenolic ring, other than two hydrogen-bonding groups
such as a phenolic hydroxyl group and another hydroxyl
group located at a suitable position on the molecule. The
C, D rings on the natural hormone, 17L-estradiol (1), play
an important role in stabilizing the ligand^receptor com-
plex by hydrophobic interactions. The size of the carbor-
ane cage seems to be appropriate for the hydrophobic
skeletal structure in place of the C, D ring structure of
1. Substitution of the two carbon atoms of the carborane
isomers should allow suitable ¢xation of the direction of
the functional groups. On the basis of these considera-
tions, we designed the compound BE120 (2c), which seems
to contain all the essential molecular recognition compo-
nents for ER. Fig. 1 shows a structural comparison of
17L-estradiol (1) and 2c. As shown in Fig. 1, we also de-
signed compounds 2a, 2b and 2d^f to evaluate the e¡ects
of substituents and of the distance of the aliphatic hydrox-
yl group from the hydrophobic skeleton. In icosahedral
Fig. 1. Structures of 17L-estradiol (1) and designed compounds (2). (Bottom) Structural comparison of 1 and 2c.
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cage structures throughout this paper, closed circles (b)
represent carbon atoms and other vertices represent BH
units.
2.2. Ligand synthesis
The designed molecules 2 were synthesized from 1,12-
dicarba-closo-dodecaborane (p-carborane, 3) as shown in
Fig. 2. 1-(4-Methoxyphenyl)-1,12-dicarba-closo-dodeca-
borane (4a), which was prepared by coupling of the C-
copper (I) derivative of 3 with 4-iodoanisole in dimethoxy-
ethane in the presence of pyridine in 60% yield [25], was
demethylated with boron tribromide to a¡ord compound
2a in 93% yield. The methoxyphenylcarborane 4a was
converted to the C-methoxycarbonyl derivative 5 by reac-
tion of the lithiate of 4a with methyl chloroformate (91%).
After reduction of 5 with LiAlH4, demethylation gave
1-hydroxymethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (BE120, 2c) in 98% yield. 1-Hydroxy-12-(4-
hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2b) was
prepared by oxidation of the lithiate of 4a with benzoyl
peroxide [26] followed by demethylation (75%). Hydrolysis
of the ester group of 5 followed by demethylation a¡orded
12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane-1-
carboxylic acid (2f) in 98% yield. The acid 4f was con-
verted to the C-t-butoxycarbonylamino derivative (6) in
41% yield by means of the modi¢ed Curtius rearrangement
[27] employing diphenylphosphoryl azide (DPPA), 4-N,N-
dimethylaminopyridine (DMAP) and tert-butanol. Depro-
tection of the Boc group of 6 followed by demethylation
gave 1-amino-12-(4-hydroxyphenyl)-1,12-dicarba-closo-do-
decaborane (2g) in a quantitative yield. Compound 4a was
converted to 4d by reaction of the lithiate of 4a with 2-(2-
bromoethoxy)tetrahydro-2H-pyran followed by deprotec-
tion of the THP group with p-toluenesulfonic acid (45%).
Demethylation of the methoxy group gave 1-hydroxyeth-
yl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane
(2d) in 88% yield. Similarly, introduction of a C3 unit into
4a a¡orded 1-hydroxypropyl-12-(4-hydroxyphenyl)-1,12-
dicarba-closo-dodecaborane (2e).
2.3. Transactivational properties and ER-binding a⁄nity of
the designed carborane-containing molecules
The estrogenic activities of the synthesized compounds
were examined by the luciferase reporter gene assay [28],
in which a rat ERK expression plasmid [29] and a reporter
plasmid, which contains ¢ve copies of estrogen response
elements, are transiently transfected into COS-1 cells. 17L-
Estradiol at 1U10310^1U1038 M induced the expression
of luciferase in a dose-dependent manner. This activation
by 17L-estradiol was dependent upon the expression of ER
Fig. 2. Synthetic route used for the preparation of the estrogen ligands bearing carborane. Key: (a) (1) n-BuLi, CuCl/DME, (2) p-iodoanisole/pyridine,
re£ux; (b) BBr3/CH2Cl2 ; (c) (1) n-BuLi/benzene^Et2O, (2) ClCOOCH3 ; (d) LiAlH4/THF; (e) KOH/H2O^THF; (f) DPPA, Et3N, DMAP/t-BuOH re-
£ux; (g) CF3COOH/CH2Cl2 ; (h) (1) n-BuLi/benzene^Et2O, (2) (C6H5COO)2/benzene^Et2O; (i) (1) n-BuLi/benzene^Et2O, (2) Br(CH2)nOTHP; (j) p-
TsOHWH2O/MeOH.
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and was completely inhibited by estrogen antagonists (ta-
moxifen and ICI 164,384). The results of the estrogenic
activity assay of our carborane-containing molecules
(2a^g) are summarized in Fig. 3. Compound 2a, which is
a simple phenol bearing p-carboranyl at the 4-position,
exhibited potent transcriptional activity in the concentra-
tion range of 1U10310^1U1038 M; its potency is much
higher than that of 4-alkylphenols. 1-Phenyl-1,12-dicarba-
closo-dodecaborane, which lacks the hydroxyl group,
showed no activity. On the other hand, the activity of
compound 2b, which has a second hydrogen-bonding
group on carbon of the carborane cage, was signi¢cantly
increased. The potency of 2b was greater than that of 17L-
estradiol. BE120 (2c), which has a hydroxymethyl group
on the carborane cage, a¡orded the most potent activity,
being at least 10 times more potent than 17L-estradiol.
Further insertion of methylene units in the substituent
on the carborane cage (2d and 2e) decreased the activity.
The activity of 2g with an amino group on the carborane
cage seemed to be somewhat stronger than that of 17L-
estradiol, and 2f with a carboxylic acid moiety exhibited
moderate activity.
ERK-binding assays were performed on the three active
compounds (2a, 2c and 2g) and 17L-estradiol to con¢rm
that the gene-regulatory activity correlated with the bind-
ing a⁄nity for the ERK. The assays were done by mea-
surement of inhibition of [6,7-3H]17L-estradiol binding
(Kd = 0.4 nM) to human recombinant ERK (PanVera), us-
ing the nitrocellulose ¢lter binding assay method. The
ERK-binding data for these compounds are consistent
with the results of the luciferase reporter gene assay. Com-
pounds 2a and 2g showed strong a⁄nity for ERK ; their
potency was almost the same as that of 17L-estradiol. The
most active compound in the luciferase reporter gene as-
say, 2c, also showed the highest a⁄nity for ERK, and its
a⁄nity was higher than that of 17L-estradiol. The Ki val-
ues of 2a, 2c, and 2g for ERK were 0.40, 0.10, and 0.65
nM, respectively.
2.4. Structure^activity relations of the carborane-containing
estrogens
To investigate the relation between the activity and the
geometry and separation distance of the two hydroxyl
groups on the phenylcarborane skeleton, we designed
and synthesized compounds bearing a para-substituent
on the carborane cage and a 3-hydroxyl group on the
benzene nucleus (7a^e), compounds bearing a substituted
meta-carborane cage and a 4-hydroxyl group on the ben-
zene nucleus (8a^e) and compounds bearing a substituted
meta-carborane cage and a 3-hydroxyl group on the ben-
zene nucleus (9a^e), in the same manner as described for
2a^2e (Fig. 4). The transcriptional activity of compounds
7, 8, and 9 is summarized in Fig. 5. The activity of the
compounds bearing a para-substituent on the carborane
cage and a 3-hydroxyl group on the benzene nucleus (3)
was somewhat weaker than that of 2, and showed the
same tendency upon insertion of methylene groups as in
the series of 2. However, the potency of 1-hydroxymethyl-
12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane 7c
was still greater than that of 17L-estradiol. The activity
Fig. 3. Transcriptional activation by the estrogen ligands bearing car-
borane (2a^g). COS-1 cells were transfected with EREx5-pGL-TK and
pCl-rERK and incubated with the compounds at the indicated concen-
trations (10310^1038 M). Results are shown as means þ S.D. for tripli-
cate transfections.
Fig. 4. Designed compounds for the structure^activity study of carbo-
rane-containing estrogens.
Fig. 5. Transcriptional activation by the estrogen ligands bearing car-
borane (7^9). COS-1 cells were transfected with EREx5-pGL-TK and
pCl-rERK and incubated with the compounds at the indicated concen-
trations (10310^1038 M). Results are shown as means þ S.D. for tripli-
cate transfections.
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of the compounds bearing a meta-substituent on the car-
borane cage and a 4-hydroxyl group on the benzene nu-
cleus (8) was weaker than that of 7. Further, the activity of
the compounds bearing a meta-substituent on the carbor-
ane cage and a 3-hydroxyl group on the benzene nucleus
(9) was greatly decreased, being similar to that of the
typical estrogenic alkylphenol 4-tert-octylphenol.
2.5. E¡ects of the carborane-containing estrogens on uterine
atrophy and bone loss in ovariectomized mice
Estrogen de¢ciency results in uterine atrophy and a
marked bone loss, and these phenomena can be restored
by estrogen administration [30]. Using ovariectomized
(OVX) mice, we compared the e¡ects of 17L-estradiol
and 2c on the uterus. The uterine weight decreased mark-
edly in OVX mice, indicating that the mice were estrogen-
de¢cient as shown in Fig. 6. As reported previously, 17L-
estradiol (100 ng/day) restored the decreased uterine
weight in OVX mice to a level higher than that of the
sham-operated mice. Compound 2c (100 ng/day) also re-
stored the uterine weight of OVX mice, and its potency
was similar to that of 1 (Fig. 6A). This indicates that 2c
exhibits a potent estrogenic action in the uterus in vivo.
To determine the e¡ects of 2c on bone mass, OVX mice
were treated for 4 weeks with 100 ng/day of 2c and the
femurs were subjected to radiographic analysis. X-ray
analysis showed a marked loss of mineralized cancellous
bone, especially in the distal metaphysis of the femur, in
OVX mice [31]. Treatment with 17L-estradiol or 2c at 100
ng/day markedly and similarly prevented the bone loss in
the distal metaphysis in OVX mice (Fig. 6B). The e¡ects of
2c on bone mass were determined by measuring bone min-
eral density (BMD) at a distal region of the femur. BMD
was signi¢cantly reduced by OVX but recovered com-
pletely on the administration of 100 ng/day of 2c to the
sham level. 17L-Estradiol at the same dosage also restored
the BMD, as reported previously. These results suggest
that 2c binds to estrogen receptor(s) present in uterus
and bone, and exhibits estrogen-like e¡ects in both tissues.
3. Discussion
Recent studies on the three-dimensional structure of the
complex formed by 17L-estradiol and the human ERK li-
gand-binding domain (hERKLBD) have revealed the
structural requirements for the appearance of estrogenic
activity [32,33]. 17L-Estradiol is oriented in the hERK li-
gand-binding pocket by two types of contacts : hydrogen
bonding at both ends and hydrophobic van der Waals
contacts along the body of the skeleton. The phenolic
hydroxyl group is hydrogen-bonded to the glutamate
(Glu-353) of hERKLBD and the 17-L-hydroxyl group is
hydrogen-bonded to the N-nitrogen of His-524. Docking
simulations to this structure (1ERE: Fig. 7A) would be
useful to clarify the relation between the three-dimensional
structures and high activity of carborane-containing estro-
gens. These simulations were performed using an auto-
matic docking program (ADAM; not publicly distributed,
only available for collaborators on contract basis) [34].
The most potent carborane-containing estrogen 2c was
well-¢tted to the cavity of the X-ray structure of
hERKLBD. Compound 2c is oriented in the cavity as
shown in Fig. 7B by two types of contacts : hydrogen
bonding at both ends and hydrophobic van der Waals
contacts along the body of the skeleton, as found for
17L-estradiol (1) in the X-ray structure. Compound 2b,
Fig. 6. E¡ects of 1 and 2c on the uterine weight and bone mineral den-
sity (BMD) of femurs in OVX mice. Mice were sham-operated or OVX,
and some of the OVX mice were treated with 1^100 ng/day of 2c or
100 ng/day of 1 immediately after the operation. Numbers in parenthe-
ses are doses of the test compounds per day (ng). At 4 weeks after the
operation, uterine weight (A) and BMD of the distal femur (B) were
measured. The upper panel in B shows soft X-ray radiograms of the fe-
murs collected from animals of each group. Note that marked bone loss
occurred in the femoral cancellous bone in OVX mice, and that the
bone loss was completely prevented by the treatment with 100 ng/day of
2c or 1. Data are expressed as the means þ S.E.M. of 6^8 mice.
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with a hydroxyl group directly substituted on the carbor-
ane cage, and the 3-hydroxy isomer 7c were also well-¢tted
to the cavity of hERKLBD (Fig. 7C,D). Table 1 shows the
heteroatom^heteroatom distances of compounds 2a, 2b,
2c, 3b, 7c, 8c, and 9c in the most stable docking models,
and that in the crystal structure of 1. The relation between
heteroatom^heteroatom distances and biological activity
suggested that three distances within 3.2 Aî seem to be
Fig. 7. The structure of the complex formed by 17L-estradiol (1) (A) and hERKLBD and the most stable docking models for 2c (B), 2b (C), 7c (D), 2a
(E), and 4-(1-adamantyl)phenol (F) to the hERKLBD. The colored cage represents the allowed region for carbon and boron atoms in ligands, calcu-
lated from the protein structure. Intermolecular hydrogen bonds (distance less than 3.2 Aî ) are shown with yellow lines.
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e¡ective for hydrogen bondings. However, the interactions
of the ligands to the receptor cannot be explained only in
terms of hydrogen bonding, but also hydrophobic interac-
tion. The lack of one hydrogen bond might be compen-
sated for by an e¡ective hydrophobic interaction. The hy-
drophobic interaction along the spherical carborane cage
seems to produce a stronger interaction than that in the
case of 17L-estradiol. This may be the reason for the high
activity of compound 2a, which lacks a hydroxyl group for
hydrogen bonding to the N-nitrogen of His-524 (Fig. 7E).
Compound 2a has signi¢cant potency compared to well-
known estrogenic 4-alkylphenols [35], 4-cycloalkylphenols
[36], and 4-(1-adamantyl)phenol [36] (Fig. 7F). Therefore,
use of this new hydrophobic and spherical component, the
carborane cage, for molecular drug design should make it
possible to develop a wide variety of biologically active
molecules, especially nuclear receptor ligands.
In summary, we have developed novel carborane-con-
taining molecules with potent estrogenic activity. The
unique character of biologically active molecules contain-
ing a carborane skeleton may give rise to unusual mem-
brane transport characteristics and metabolism, compared
with conventional active molecules. The superagonistic
properties of the carborane-containing compounds raise
the possibility that structure^function studies could lead
to the development of more selective estrogen agonists
and antagonists, which could be useful as therapeutic
agents for a wide variety of conditions.
4. Signi¢cance
Carboranes (dicarba-closo-dodecaboranes) are a class of
carbon-containing polyhedral boron-cluster compounds
having remarkable thermal stability and exceptional hy-
drophobicity. These features of carboranes may allow
their use as a hydrophobic pharmacophore in biologically
active molecules that interact hydrophobically with recep-
tors. We therefore designed candidate estrogen-receptor-
binding compounds having carborane as a hydrophobic
moiety (2) and synthesized them. Their estrogenic activity
was examined by the luciferase reporter gene assay using
COS-1 cells transfected with rat ERK expression plasmid
and an appropriate reporter plasmid. The most potent
compound bearing a carborane cage (BE120, 2c) exhibited
potent activity in the concentration range of 1U10310^
1U1038 M; its potency is at least 10-fold greater than
that of 17L-estradiol. In vitro ERK-binding data for these
compounds were consistent with the results of the lucifer-
ase reporter gene assay. These results con¢rm that the
gene-regulatory activity of the carborane-containing com-
pounds is correlated with their binding a⁄nity for the ER.
The most active compound in the luciferase reporter gene
assay, BE120, also showed the highest a⁄nity for ERK.
The compound also showed potent in vivo e¡ects on the
recovery of uterine weight and bone loss in OVX mice.
Development of the potent carborane-containing estrogen-
ic agonists described here should yield novel candidate
therapeutic agents, especially selective ER modulators.
Furthermore, the suitability of the spherical carborane
cage for binding to the cavity of ERKLBD should provide
a basis for a similar approach to developing novel ligands
for other steroid receptors.
5. Materials and methods
5.1. Synthesis
5.1.1. 1-(4-Methoxyphenyl)-1,12-dicarba-closo-dodecaborane
(4a)
To a solution of 1,12-dicarba-closo-dodecaborane (3, 3.5 g,
24.3 mmol) in 1,2-dimethoxyethane (95 ml) was added dropwise
a 1.54 M solution of n-BuLi in hexane (16.6 ml, 25.6 mmol) at
0‡C under Ar. The mixture was stirred at room temperature for
30 min, and CuCl (3.13 g, 31.6 mmol) was added in one portion.
Stirring was continued at room temperature for 1 h, then pyridine
(14.7 ml, 183 mmol) was added, and 4-iodoanisole (5.97 g, 25.5
mmol) was further added in one portion, and the mixture was
heated at 100‡C for 48 h. After cooling, the reaction mixture was
diluted with Et2O and stirred at room temperature for 3 h. In-
soluble materials were ¢ltered o¡ through Celite. The ¢ltrate was
washed with 2 N HCl, aq. Na2S2O3, H2O, and brine, dried over
Na2SO4, then concentrated. Puri¢cation by silica gel column
chromatography (eluent: hexane to hexane/AcOEt, 10:1) gave
4a (60%) and 1,12-bis(4-methoxyphenyl)-1,12-dicarba-closo-do-
Table 1
Heteroatom^heteroatom distances in Aî (hydrogen bond distances) in the most stable docking models
Ligand Phenolic-OH/353Glu Phenolic-OH/349Arg Alcoholic-OH/524His Einter (kcal/mol)a
1 2.59 3.36 2.57 354.67
2a 2.71 3.17 ^ 345.88
2b 2.80 3.24 2.91 347.76
2c 2.64 2.89 2.82 351.60
7b 3.41 (4.59) 3.04 345.63
7c 3.14 (4.08) 2.80 348.00
8c 2.97 3.32 (5.05) 349.17
9c 3.09 (3.98) 2.93 345.34
aEinter : interaction energy between protein and ligand in the most stable docking models.
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decaborane (13%). 4a : colorless needles (hexane): mp 102^103‡C;
1H NMR (CDCl3) N 1.50^3.30 (10 H, br m), 2.75 (1 H, br s), 3.74
(3 H, s), 6.68 (2 H, d, J = 9.1 Hz), 7.11 (2 H, d, J = 9.1 Hz);
HRMS calc. for C9H18B10O 250.2361, found 250.2374.
5.1.2. 1-(4-Hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2a)
To a solution of 4a (100 mg, 0.399 mmol) in CH2Cl2 (1 ml)
was added dropwise a 1 M solution of BBr3 in CH2Cl2 (0.48 ml)
at 378‡C. The mixture was stirred at room temperature for 2 h,
then poured into ice water, and extracted with CH2Cl2. The or-
ganic layer was washed with brine, dried over Na2SO4, and con-
centrated. Puri¢cation by silica gel £ash column chromatography
(eluent: hexane/AcOEt, 10:1) gave 2a (93%). 2a : colorless needles
(CH2Cl2^hexane); mp 193^194‡C; 1H NMR (CDCl3) N 1.40^3.20
(10 H, br m), 2.75 (1 H, br s), 4.73 (1 H, br s), 6.61 (2 H, d,
J = 9.0 Hz), 7.07 (2 H, d, J = 9.0 Hz); HRMS calcd for
C8H16B10O 236.2204, found 236.2227. Anal. calcd for
C8H16B10O: C, 40.66; H, 6.82. Found C, 40.67; H, 6.79.
5.1.3. 1-Hydroxy-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (2b)
To a solution of 4a (300 mg, 1.20 mmol) in benzene/Et2O (2:1,
3 ml) was added dropwise a 1.54 M solution of n-BuLi in hexane
(1.56 ml, 2.40 mmol) at 0‡C under Ar. The mixture was stirred at
room temperature for 30 min. The solution was cooled at 0‡C
and benzyl peroxide (145 mg, 0.601 mmol) in benzene/Et2O (2:1,
3 ml) was added dropwise, then the mixture was stirred at room
temperature for 2 h. The reaction was quenched with 10% aque-
ous HCl and extracted with AcOEt. The organic layer was
washed with brine, dried over Na2SO4, and concentrated. Puri¢-
cation by silica gel £ash column chromatography (eluent: hexane/
AcOEt, 10:1) gave 4b (75%) as a colorless solid: 1H NMR
(CDCl3) N 1.60^3.40 (10 H, br m), 2.87 (1 H, s), 3.73 (3 H, s),
6.67 (2 H, d, J = 8.6 Hz), 7.12 (2 H, d, J = 8.6 Hz); HRMS calcd
for C9H18B10O2 266.2310, found 266.2304. 2b was prepared from
4b by the same method as used for the preparation of 2a. Puri-
¢cation by recrystallization gave 2b (95%). 2b : colorless needles
(CH2Cl2^hexane); mp 181^183‡C; 1H NMR (CDCl3) N 1.50^3.40
(10 H, br m), 4.70 (1 H, bs), 6.60 (2 H, d, J = 8.8 Hz), 7.07 (2 H,
d, J = 8.8 Hz); HRMS calcd for C8H16B10O2 252.2153, found
252.2173. Anal. calcd for C8H16B10O2W1/2H2O: C, 36.77; H,
6.56. Found C, 36.42, H, 6.57.
5.1.4. 1-Methoxycarbonyl-12-(4-methoxyphenyl)-1,12-dicarba-
closo-dodecaborane (5)
To a solution of 4a (500 mg, 2.00 mmol) in benzene/Et2O (2:1,
15 ml) was added dropwise a 1.54 M solution of n-BuLi in hex-
ane (1.56 ml, 2.40 mmol) at 0‡C under Ar. The mixture was
stirred at room temperature for 30 min and cooled to 0‡C, then
methyl chloroformate (227 mg, 2.40 mmol) was added dropwise
and stirring was continued at room temperature for 3 h. The
reaction was quenched with water and the whole was extracted
with AcOEt. The organic layer was washed with brine, dried over
Na2SO4, and concentrated. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 50:1) gave 5 (91%). 5 :
colorless prisms (hexane); mp 108^109‡C; 1H-NMR (CDCl3) N
1.60^3.40 (10 H, br m), 3.65 (3 H, s), 3.74 (3 H, s), 6.68 (2 H, d,
J = 9.1 Hz), 7.08 (2 H, d, J = 9.1 Hz); Anal. calcd for
C11H20B10O3 : C, 42.84; H, 6.54. Found C, 42.82; H, 6.29.
5.1.5. 1-Hydroxymethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (2c)
To a suspension of LiAlH4 (25.8 mg, 0.680 mmol) in THF (3
ml) was added dropwise 5 (150 mg, 0.486 mmol) in THF (2 ml) at
0‡C, and the mixture was stirred at room temperature for 2.5 h.
The reaction was quenched with 2 N HCl and the whole was
extracted with AcOEt. The organic layer was washed with water
and brine, dried over Na2SO4, then concentrated to give 1-hy-
droxymethyl-12-(4-methoxyphenyl)-1,12-dicarba-closo-dodeca-
borane (4c) (99%). 4c : colorless prisms (CH2CH2^hexane); mp
151^152‡C; 1H NMR (CDCl3) N 1.50^3.30 (10 H, br m), 3.55 (2
H, s), 3.74 (3 H, s), 6.68 (2 H, d, J = 9.2 Hz), 7.11 (2 H, d, J = 9.2
Hz). Anal. calcd for C10H20B10O2 : C, 42.84; H, 7.19. Found C,
42.94; H, 6.96. 2c was prepared from 4c by the same method as
used for the preparation of 2a. Puri¢cation by silica gel £ash
column chromatography (eluent: hexane/AcOEt, 4:1) gave 2c
(100%). 2c : colorless needles (CH2Cl2^hexane); mp 184^185‡C;
1H NMR (CDCl3) N 1.50^3.30 (10 H, br m), 3.54 (2 H, s), 4.87 (1
H, br), 6.61 (2 H, d, J = 8.9 Hz), 7.06 (2 H, d, J = 8.9 Hz); HRMS
calcd for C9H18B10O2 266.2310, found 266.2310. Anal. calcd for
C9H18B10O2 : C, 40.59; H, 6.81. Found C, 40.30, H, 6.81.
5.1.6. 1-Hydroxyethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (2d)
To a solution of 4a (200 mg, 0.80 mmol) in benzene/Et2O (2:1,
7.5 ml) was added dropwise a 1.54 M solution of n-BuLi in
hexane (0.623 ml, 0.953 mmol) at 0‡C under Ar. The mixture
was stirred at room temperature for 30 min and cooled to 0‡C,
then O-tetrahydropyranyl-2-bromoethanol (231 mg, 1.20 mmol)
was added dropwise and stirring was continued at room temper-
ature for 15 h. The reaction was quenched with water and the
whole was extracted with AcOEt. The organic layer was washed
with brine, dried over Na2SO4, and concentrated. Puri¢cation by
silica gel £ash column chromatography (eluent: hexane/CH2Cl2,
2:1) gave the C-alkylated product (45%). 1H NMR (CDCl3) N
1.45^1.82 (6 H, m), 1.50^3.20 (10 H, br m), 1.98 (2 H, t, J = 7.0
Hz), 3.17 (1 H, dt, J = 9.9, 7.6 Hz), 3.45^3.51 (1 H, m), 3.55 (1 H,
dt, J = 10.1, 7.6 Hz), 3.73 (3 H, s), 3.80 (1 H, m), 4.49 (1 H, m),
6.67 (2 H, d, J = 9.2 Hz), 7.10 (2 H, d, J = 9.2 Hz). The compound
(112 mg, 0.296 mmol) was dissolved in MeOH/CH2Cl2 (3:1, 4
ml), and TsOHWH2O (5.6 mg, 0.0294 mmol) was added. The mix-
ture was stirred at room temperature for 15 h. The reaction was
quenched with saturated aqueous NaHCO3, then the mixture was
extracted with CH2Cl2. The organic layer was washed with brine,
dried over Na2SO4, and concentrated to give 4d (100%). 1H
NMR (CDCl3) N 1.50^3.30 (10 H, br m), 1.95 (2 H, t, J = 7.0
Hz), 3.48 (1 H, t, J = 7.0 Hz), 3.73 (3 H, s), 6.67 (2 H, d, J = 9.0
Hz), 7.10 (2 H, d, J = 9.0 Hz). 2d was prepared from 4d by the
same method as used for the preparation of 2a. Puri¢cation by
silica gel £ash column chromatography (eluent: hexane/AcOEt,
4:1) gave 2d (88%). 2d : colorless needles (CH2Cl2^hexane); mp
180^181‡C; 1H NMR (CDCl3) N 1.30 (1 H, t, J = 5.1 Hz), 1.50^
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3.30 (10 H, br m), 1.95 (2 H, t, J = 7.0 Hz), 3.48 (1 H, dt, J = 7.0,
5.1 Hz), 4.75 (1 H, s), 6.60 (2 H, d, J = 9.0 Hz), 7.06 (2 H, d,
J = 9.0 Hz). HRMS calcd for C10H20B10O2 280.2466, found
280.2462. Anal. calcd for C10H20B10O2 : C, 42.84; H, 7.19. Found
C, 42.79; H, 7.46.
5.1.7. 1-Hydroxyethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (2e)
4a (750 mg, 3.00 mmol) was converted to 4e (64%) in the same
manner as used for the preparation of 4d. 1H NMR (CDCl3) N
1.17 (1 H, bs), 1.40^3.30 (10 H, br m), 1.46 (2 H, m), 1.78 (2 H,
m), 3.50 (2 H, m), 3.73 (3 H, s), 6.67 (2 H, d, J = 9.0 Hz), 7.10 (2
H, d, J = 9.0 Hz). 2e was prepared from 4e by the same method as
used for the preparation of 2a. Puri¢cation by silica gel £ash
column chromatography (eluent: hexane/AcOEt, 4:1) gave 2d
(92%). 2d : colorless needles (CH2Cl2^hexane); mp 185^186‡C;
1H NMR (CDCl3) N 1.10^3.30 (10 H, br m), 1.45 (2 H, m),
1.77 (2 H, m), 3.50 (2 H, t, J = 6.1 Hz), 4.70 (1 H, bs), 6.60 (2
H, d, J = 9.0 Hz), 7.06 (2 H, d, J = 9.0 Hz). Anal. calcd for
C11H22B10O2 : C, 44.88; H, 7.53. Found C, 44.58, H, 7.32.
5.1.8. 1-Hydroxycarbonyl-12-(4-hydroxyphenyl)-1,12-dicarba-
closo-dodecaborane (2f)
To a solution of 5 (260 mg, 0.843 mmol) in THF (3 ml) was
added 1 N KOH (4.22 ml), and the mixture was stirred at room
temperature for 17 h. The reaction was quenched with 2 N HCl
and the whole was extracted with AcOEt. The organic layer was
washed with water and brine, dried over Na2SO4, then concen-
trated to give 1-hydroxycarbonyl-12-(4-methoxyphenyl)-1,12-di-
carba-closo-dodecaborane (4f) (quant.). 1H NMR (DMSO-d6) N
1.60^3.40 (10 H, br m), 3.69 (3 H, s), 6.78 (2 H, d, J = 9.1 Hz),
7.08 (2 H, d, J = 9.1 Hz), 14.06 (1 H, br). 2f was prepared from 4f
by the same method as used for the preparation of 2b (quant.).
2f : colorless needles (AcOEt^CH2Cl2^hexane); mp 249^252‡C;
1H NMR (DMSO-d6) N 1.60^3.40 (10 H, br m), 6.57 (2 H, d,
J = 8.8 Hz), 6.94 (2 H, d, J = 8.8 Hz), 9.58 (1 H, s), 14.04 (1 H,
br); HRMS calcd for C9H16B10O3 280.2102, found 280.2114.
Anal. calcd for C9H16B10O3 : C, 38.56; H, 5.75. Found C,
38.39, H, 5.82.
5.1.9. 1-tert-Butoxycarbonylamino-12-(4-methoxyphenyl)-1,12-
dicarba-closo-dodecaborane (6)
A mixture of 4f (140 mg, 0.476 mmol), Et3N (144 mg, 1.42
mmol), 4-dimethylaminopyridine (11.6 mg, 0.0949 mmol) and
diphenylphosphoryl azide (196 mg, 0.712 mmol) in t-BuOH (8
ml) was re£uxed for 24 h, then concentrated. The residue was
taken up in AcOEt, washed with water and brine, dried over
Na2SO4, then concentrated. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 20:1) gave 6 (41%). 6 :
colorless needles (hexane); mp 148^149‡C; 1H NMR (CDCl3) N
1.39 (9 H, s), 1.60^3.40 (10 H, br m), 3.73 (3 H, s), 4.89 (1 H, s),
6.67 (2 H, d, J = 9.0 Hz), 7.11 (2 H, d, J = 9.0 Hz).
Fig. 8. Synthetic route used for the preparation of the estrogen ligands bearing carborane (7). Key: (a) (1) n-BuLi, CuCl/DME, (2) m-iodoanisole/pyri-
dine, re£ux; (b) BBr3/CH2Cl2 ; (c) (1) n-BuLi/benzene^Et2O, (2) ClCOOCH3 ; (d) LiAlH4/THF; (e) (1) n-BuLi/benzene^Et2O, (2) (C6H5COO)2/benzene^
Et2O; (f) n-BuLi/benzene^Et2O, (2) Br(CH2)nOTHP; (g) p-TsOHWH2O/MeOH.
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5.1.10. 1-Amino-12-(4-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (2g)
To a solution of 6 (62 mg, 0.170 mmol) in CH2Cl2 (2 ml) was
added TFA (0.4 ml), and the mixture was stirred at room temper-
ature for 2.5 h. The reaction was quenched with saturated aque-
ous NaHCO3 and the whole was extracted with CH2Cl2. The
organic layer was washed with brine, dried over Na2SO4, then
concentrated to give 1-amino-12-(4-methoxyphenyl)-1,12-dicarba-
closo-dodecaborane (100%) as colorless needles (CH2Cl2^hexane).
mp 155^156‡C; 1H NMR (CDCl3) N 1.50^3.30 (10 H, br m), 3.73
(3 H, s), 6.67 (2 H, d, J = 9.0 Hz), 7.11 (2 H, d, J = 9.0 Hz). 2g
was prepared from the amine by the same method as used for the
preparation of 2a. The reaction mixture was poured into cold
saturated aqueous NaHCO3 and extracted with AcOEt. The or-
ganic layer was washed with brine, dried over Na2SO4 and con-
centrated. Puri¢cation by silica gel £ash column chromatography
(eluent: hexane/AcOEt, 5:1) gave 2g (100%). 2g : colorless needles
(CH2Cl2^hexane); mp 169^171‡C; 1H NMR (CDCl3) N 1.50^3.30
(10 H, br m), 2.05 (2 H, br s), 4.81 (1 H, s), 6.59 (2 H, d, J = 9.0
Hz), 7.06 (2 H, d, J = 9.0 Hz); HRMS calcd for C8H17B10NO
251.2313, found 251.2299. Anal. calcd for C8H17B10NO: C,
36.91; H, 6.97; N, 5.38. Found C, 37.20; H, 6.90; N, 5.28.
5.1.11. 1-(3-Methoxyphenyl)-1,12-dicarba-closo-dodecaborane
(10a)
Compound 10a was prepared from 1,12-dicarba-closo-dodeca-
borane (3) and 3-iodoanisole by the same method as used for
preparation of 4a (Fig. 8). Puri¢cation by silica gel column chro-
matography (eluent: hexane/AcOEt, 100:1 to 10:1) gave 10a
(61%) and 1,12-bis(3-methoxyphenyl)-1,12-dicarba-closo-dodeca-
borane (10%). 10a : colorless solid; 1H NMR (CDCl3) N 1.50^
3.30 (10 H, br m), 2.78 (1 H, br s), 3.75 (3 H, s), 6.73^6.76 (2 H,
m), 6.79 (1 H, m), 7.08 (1 H, m).
5.1.12. 1-(3-Hydroxyphenyl)-1,12-dicarba-closo-dodecaborane
(7a)
Compound 7a was prepared from 10a by the same method as
used for preparation of 2a. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 10:1) gave 7a (100%).
7a : colorless needles (CH2Cl2^hexane); mp 163^164‡C; 1H NMR
(CDCl3) N 1.50^3.30 (10 H, br m), 2.78 (1 H, br s), 4.67 (1 H, s),
6.66^6.69 (2 H, m), 6.78 (1 H, m), 7.03 (1 H, m). Anal. calcd for
C8H16B10O: C, 40.66; H, 6.82. Found C, 40.36; H, 6.64.
5.1.13. 1-Hydroxy-12-(3-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (7b)
Compound 10b was prepared from 10a by the same method as
used for preparation of 4b. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 10:1) gave 10b (65%) as
colorless solid: 1H NMR (CDCl3) N 1.60^3.40 (10 H, br m), 2.97
(1 H, s), 3.74 (3 H, s), 6.72^6.77 (2 H, m), 6.80 (1 H, ddd, J = 1.0,
1.9, 7.9 Hz), 7.07 (1 H, dt, J = 0.9, 7.9 Hz). Compound 7b was
prepared from 10b by the same method as used for preparation of
2b. Puri¢cation by silica gel £ash column chromatography (elu-
ent: hexane/AcOEt, 5:1) gave 7b (96%). 7b : colorless needles
(CH2Cl2^hexane); mp 185^186‡C; 1H NMR (CDCl3) N 1.50^
3.40 (10 H, br m), 4.70 (1 H, br), 6.66^6.71 (2 H, m), 6.78 (1
H, br d) 7.02 (1 H, t, J = 8.0 Hz). Anal. calcd for C8H16B10O2 : C,
38.08; H, 6.39. Found C, 38.31; H, 6.43.
5.1.14. 1-Methoxycarbonyl-12-(3-methoxyphenyl)-1,12-dicarba-
closo-dodecaborane (11)
Compound 11 was prepared from 10a by the same method as
used for preparation of 5. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 20:1) gave 11 (87%) as
colorless solid: 1H NMR (CDCl3) N 1.60^3.50 (10 H, br m), 3.65
(3 H, s), 3.75 (3 H, s), 6.71^6.78 (3 H, m).
5.1.15. 1-Hydroxymethyl-12-(3-hydroxyphenyl)-1,12-dicarba-
closo-dodecaborane (7c)
Compound 7c was prepared from 11 by the same method as
used for preparation of 2c. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 4:1) gave 7c (100%). 7c :
colorless needles (CH2Cl2^hexane); mp 134^135‡C; 1H NMR
(CDCl3) N 1.50^3.30 (10 H, br m), 1.58 (1 H, t, J = 7.3 Hz),
3.55 (2 H, d, J = 7.3 Hz), 4.70 (1 H, s), 6.67^6.69 (2 H, m),
6.77 (1 H, m), 7.03 (1 H, m). Anal. calcd for C9H18B10O2 : C,
40.59; H, 6.81. Found C, 40.35; H, 6.51.
5.1.16. 1-Hydroxyethyl-7-(3-hydroxyphenyl)-1,12-dicarba-
closo-dodecaborane (7d)
Compound 10d was prepared from 10a by the same method as
used for preparation of 4d (66%). 10d : colorless solid; 1H NMR
(CDCl3) N 1.28 (1 H, t, J = 5.6 Hz), 1.50^3.30 (10 H, br m), 1.95
(2 H, t, J = 7.0 Hz), 3.48 (2 H, dt, J = 5.6, 7.0 Hz), 3.74 (3 H, s),
6.73^6.79 (3 H, m), 7.07 (1 H, m). Compound 7d was prepared
from 10d by the same method as used for preparation of 2d.
Puri¢cation by silica gel £ash column chromatography (eluent:
hexane/AcOEt, 3:1) gave 7d (92%). 7d : colorless needles
(CH2Cl2); mp 186^187‡C; 1H NMR (CDCl3) N 1.30 (1 H, t,
J = 4.9 Hz), 1.50^3.30 (10 H, br m), 1.95 (2 H, t, J = 7.0 Hz)
3.48 (2 H, dt, J = 4.9, 7.0 Hz), 4.74 (1 H, s), 6.65^6.69 (2 H,
m), 6.76 (1 H, m), 7.02 (1 H, m); HRMS calcd for C10H20B10O2
280.2466; found 280.2466. Anal. calcd for C10H20B10O2W0.12O:
C, 42.56; H, 7.21. Found C, 42.39; H, 6.95.
5.1.17. 1-Hydroxypropyl-12-(3-hydroxyphenyl)-1,12-dicarba-
closo-dodecaborane (7e)
Compound 10e was prepared from 10a by the same method as
used for preparation of 4e (69%). 10e : colorless solid; 1H NMR
(CDCl3) N 1.14 (1 H, t, J = 5.2 Hz), 1.40^3.30 (10 H, br m), 1.45
(2 H, m), 1.78 (2 H, m), 3.50 (2 H, dt, J = 5.2, 6.1 Hz), 3.74
(3 H, s), 6.72^6.80 (3 H, m), 7.07 (1 H, m). Compound 7e
was prepared from 10e by the same method as used for pre-
paration of 2e. Puri¢cation by silica gel £ash column chro-
matography (eluent: hexane/AcOEt, 3:1) gave 2e (99%). 2e :
colorless needles (CH2Cl2); mp 211^212‡C; 1H NMR (DMSO-
d6) N 1.25 (2 H, m), 1.40^3.20 (10 H, br m), 1.73 (2 H, m) 3.23
(2 H, dt, J = 5.1,5.7 Hz), 4.39 (1 H, t, J = 5.1 Hz), 6.57^6.59
(2 H, m), 6.64 (1 H, m), 7.01 (1 H, m), 9.54 (1 H, s). Anal.
calcd for C11H22B10O2 : C, 44.88; H, 7.53. Found C, 44.64; H,
7.24.
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5.1.18. 1-(4-Methoxyphenyl)-1,7-dicarba-closo-dodecaborane
(13a)
To a solution of 1,7-dicarba-closo-dodecaborane (12, 3.5 g,
24.3 mmol) in 1,2-dimethoxyethane (95 ml) was added dropwise
a 1.54 M solution of n-BuLi in hexane (16.6 ml, 25.6 mmol) at
0‡C under Ar (Fig. 9). The mixture was stirred at room temper-
ature for 30 min, then CuCl (3.13 g, 31.6 mmol) was added in one
portion and stirring was continued at room temperature for 1 h.
Pyridine (14.7 ml, 183 mmol) was added, then 4-iodoanisole (5.97
g, 25.5 mmol) was further added in one portion, and the mixture
was heated at 100‡C for 48 h. After cooling, the reaction mixture
was diluted with Et2O and stirred at room temperature for 15 h.
Insoluble materials were ¢ltered o¡ through Celite. The ¢ltrate
was washed with 2 N HCl, aq. Na2S2O3, H2O and brine, dried
over Na2SO4, then concentrated. Puri¢cation by silica gel column
chromatography (eluent: hexane to hexane/AcOEt, 30:1) gave
13a (42%) and 1,7-bis(4-methoxyphenyl)-1,7-dicarba-closo-dodec-
aborane (17%). 13a : colorless needles (hexane); mp 100^101‡C;
1H NMR (CDCl3) N 1.50^3.70 (10 H, br m), 3.04 (1 H, br s), 3.77
(3 H, s), 6.76 (2 H, d, J = 9.2 Hz), 7.33 (2 H, d, J = 9.2 Hz);
HRMS calcd for C9H18B10O 250.2361, found 250.2361.
5.1.19. 1-(4-Hydroxyphenyl)-1,7-dicarba-closo-dodecaborane (8a)
Compound 8a was synthesized from 13a by the same method
as used for preparation of 2a. Puri¢cation by silica gel £ash
column chromatography (eluent: hexane/AcOEt, 10:1) gave 8a.
8a : colorless needles (CH2Cl2^hexane); mp 180^181‡C; 1H NMR
(CDCl3) N 1.50^3.70 (10 H, br m), 3.04 (1 H, br s), 4.81 (1 H, s),
6.69 (2 H, d, J = 8.9 Hz), 7.28 (2 H, d, J = 8.9 Hz); HRMS calcd
for C8H16B10O 236.2204, found 236.2206. Anal. calcd for
C8H16B10O: C, 40.66; H, 6.82. Found: C, 40.52; H, 6.68.
5.1.20. 1-Hydroxy-7-(4-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (8b)
Compound 13b was prepared from 13a by the same method as
used for preparation of 4b. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/CH2Cl2, 1:1) gave 13b (41%) as
colorless solid: 1H NMR (CDCl3) N 1.40^4.10 (10 H, br m), 3.31
(1 H, s), 3.78 (3 H, s), 6.76 (2 H, d, J = 8.9 Hz), 7.32 (2 H, d,
J = 8.9 Hz); HRMS calcd for C9H18B10O2 266.2310, found
266.2299. Compound 8b was prepared from 13b by the same
method as used for preparation of 2b. Puri¢cation by silica gel
£ash column chromatography (eluent: hexane/AcOEt, 3:1) gave
8b (93%). 8b : colorless needles (CH2Cl2^hexane); mp 168^169‡C
1H NMR (CDCl3) N 1.40^4.00 (10 H, br m), 4.80 (1 H, br), 6.70
(2 H, d, J = 9.0 Hz), 7.28 (2 H, d, J = 9.0 Hz). Anal. calcd for
C8H16B10O2 : C, 38.08; H, 6.39. Found C, 37.84; H, 6.30.
5.1.21. 1-Methoxycarbonyl-7-(4-methoxyphenyl)-1,7-dicarba-
closo-dodecaborane (14)
Compound 14 was prepared from 13a by the same method as
used for preparation of 5. Puri¢cation by silica gel £ash column
Fig. 9. Synthetic route used for the preparation of the estrogen ligands bearing carborane (8). Key: (a) (1) n-BuLi, CuCl/DME, (2) p-iodoanisole/pyri-
dine, re£ux; (b) BBr3/CH2Cl2 ; (c) (1) n-BuLi/benzene^Et2O, (2) ClCOOCH3 ; (d) LiAlH4/THF; (e) (1) n-BuLi/benzene^Et2O, (2) (C6H5COO)2/benzene^
Et2O; (f) (1) n-BuLi/benzene^Et2O, (2) Br(CH2)nOTHP; (g) p-TsOHWH2O/MeOH.
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chromatography (eluent: hexane/AcOEt, 20:1) gave 14 (82%).
14 : colorless needles (hexane); mp 47^48‡C; 1H NMR (CDCl3)
N 1.50^3.70 (10 H, br m), 3.76 (3 H, s), 3.78 (3 H, s), 6.77 (2 H, d,
J = 9.2 Hz), 7.33 (2 H, d, J = 9.2 Hz); HRMS calcd for
C11H26B10O3 308.2416, found 308.2428.
5.1.22. 1-Hydroxymethyl-7-(4-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (8c)
Compound 8c was prepared from 14 by the same method as
used for preparation of 2c. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 3:1) gave 8c (79%). 8c :
colorless needles (CH2Cl2^hexane); mp 173^174‡C; 1H NMR
(CDCl3) N 1.50^3.80 (10 H, br m), 1.86 (1 H, br s), 3.87 (2 H,
s), 4.83 (1 H, s), 6.69 (2 H, d, J = 8.9 Hz), 7.28 (2 H, d, J = 8.9
Hz); HRMS calcd for C9H18B10O2 266.2310, found 266.2303.
Anal. calcd for C9H18B10O2 : C, 40.59; H, 6.81. Found C,
40.57; H, 6.88.
5.1.23. 1-Hydroxyethyl-7-(4-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (8d)
Compound 13d was prepared from 13a by the same method as
used for preparation of 4d (63%). 13d : colorless solid; 1H NMR
(CDCl3) N 1.20^3.30 (10 H, br m), 2.28 (2 H, t, J = 6.9 Hz), 3.67
(2 H, t, J = 6.9 Hz), 3.78 (3 H, s), 6.76 (2 H, d, J = 9.0 Hz), 7.32 (2
H, d, J = 9.0 Hz). Compound 8d was prepared from 13d by the
same method as used for preparation of 2d. Puri¢cation by silica
gel £ash column chromatography (eluent: hexane/AcOEt, 2:1)
gave 8d (90%). 8d : colorless needles (CH2Cl2^hexane); mp 156^
157‡C; 1H NMR (CDCl3) N 1.50^3.50 (10 H, br m), 2.28 (2 H, t,
J = 6.9 Hz), 3.67 (2 H, t, J = 6.9, Hz), 4.79 (1 H, s), 6.69 (2 H, d,
J = 8.9 Hz), 7.28 (2 H, d, J = 8.9 Hz); HRMS calcd for
C10H20B10O2 280.2466, found: 280.2470. Anal. calcd for
C10H20B10O2 : C, 42.84; H, 7.19. Found C, 42.53; H, 6.75.
5.1.24. 1-Hydroxypropyl-7-(4-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (8e)
Compound 13e was prepared from 13a by the same method as
used for preparation of 4e (84%). 13e : colorless solid; 1H NMR
(CDCl3) N 1.20^3.40 (10 H, br m), 1.25 (1 H, br s), 1.67 (2 H, m),
2.12 (2 H, m), 3.60 (2 H, t, J = 6.1 Hz), 3.78 (3 H, s), 6.75 (2 H, d,
J = 9.0 Hz), 7.32 (2 H, d, J = 9.0 Hz). Compound 8e was prepared
from 13e by the same method as used for preparation of 2e.
Puri¢cation by silica gel £ash column chromatography (eluent:
hexane/AcOEt, 2:1) gave 8e (82%). 8e : colorless needles
(CH2Cl2^hexane); mp 157^158‡C; 1H NMR (CDCl3) N 1.23 (1
H, t, J = 5.1 Hz), 1.40^3.80 (10 H, br m), 1.67 (2 H, m), 2.11 (2 H,
m) 3.60 (2 H, dt, J = 5.1, 5.3 Hz), 4.81 (1 H, s), 6.68 (2 H, d,
J = 8.9 Hz), 7.28 (2 H, d, J = 8.9 Hz). Anal. calcd for
C11H22B10O2 : C, 44.88; H, 7.53. Found C, 44.61; H, 7.24.
5.1.25. 1-(3-Methoxyphenyl)-1,7-dicarba-closo-dodecaborane
(15a)
Compound 15a was prepared from 1,7-dicarba-closo-dodeca-
borane (12) and 3-iodoanisole by the same method as used for
preparation of 13a (Fig. 10). Puri¢cation by silica gel column
chromatography (eluent: hexane/AcOEt, 100:1 to 50:1) gave
15a (39%) and 1,7-bis(3-methoxyphenyl)-1,7-dicarba-closo-dodec-
aborane (14%). 15a : colorless solid; 1H NMR (CDCl3) N 1.50^
3.70 (10 H, br m), 3.05 (1 H, br s), 3.79 (3 H, s), 6.82 (1 H, dd,
J = 2.4, 8.2 Hz), 6.96 (1 H, t, J = 2.4 Hz), 7.01 (1 H, br d, J = 8.2
Hz), 7.16 (1 H, t, J = 8.2 Hz).
5.1.26. 1-(3-Hydroxyphenyl)-1,7-dicarba-closo-dodecaborane (9a)
Compound 9a was synthesized from 15a by the same method
as used for preparation of 2a. Puri¢cation by silica gel £ash
column chromatography (eluent: hexane/AcOEt, 5:1) gave 9a
(100%). 9a : colorless needles (CH2Cl2^hexane); mp 140^141‡C;
1H NMR (CDCl3) N 1.40^3.80 (10 H, br m), 3.05 (1 H, br s),
4.70 (1 H, s), 6.75 (1 H, dd, J = 2.4, 8.1 Hz), 6.90 (1 H, t, J = 2.4
Hz), 6.99 (1 H, br d, J = 8.1 Hz), 7.11 (1 H, t, J = 8.1 Hz). Anal.
calcd for C8H16B10O: C, 40.66; H, 6.82. Found C, 40.48; H,
6.56.
5.1.27. 1-Hydroxy-7-(3-hydroxyphenyl)-1,12-dicarba-closo-
dodecaborane (9b)
Compound 15b was prepared from 15a by the same method as
used for preparation of 4b. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/CH2Cl2, 1:1) gave 15b (44%) as
colorless solid: 1H NMR (CDCl3) N 1.60^4.00 (10 H, br m), 3.30
(1 H, s), 3.79 (3 H, s), 6.83 (1 H, dd, J = 2.2, 8.1 Hz), 6.95 (1 H, t,
J = 2.2 Hz), 7.00 (1 H, m), 7.17 (1 H, t, J = 8.1 Hz). Compound 9b
was prepared from 15b by the same method as used for prepara-
tion of 2b. Puri¢cation by silica gel £ash column chromatography
(eluent: hexane/AcOEt, 3:1) gave 9b (100%). 9b : colorless needles
(CH2Cl2^hexane); mp 135^136‡C; 1H NMR (CDCl3) N 1.40^4.00
(10 H, br m), 4.70 (1 H, br), 6.76 (1 H, ddd, J = 1.0, 2.5, 8.1 Hz),
6.89 (1 H, t, J = 2.5 Hz), 6.99 (1 H, ddd, J = 1.0, 2.5, 8.1 Hz), 7.12
(1 H, t, J = 8.1 Hz). Anal. calcd for C8H16B10O2 : C, 38.08; H,
6.39. Found C, 37.79; H, 6.37.
5.1.28. 1-Methoxycarbonyl-7-(3-methoxyphenyl)-1,7-dicarba-
closo-dodecaborane (16)
Compound 16 was prepared from 15a by the same method as
used for preparation of 5. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 20:1) gave 16 (76%) as
colorless solid: 1H NMR (CDCl3) N 1.50^3.70 (10 H, br m), 3.77
(3 H, s), 3.79 (3 H, s), 6.84 (1 H, dd, J = 2.4, 8.2 Hz), 6.96 (1 H, t,
J = 2.4 Hz), 7.01 (1 H, br d, J = 8.2 Hz), 7.17 (1 H, t, J = 8.2 Hz).
5.1.29. 1-Hydroxymethyl-7-(3-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (9c)
Compound 9c was prepared from 16 by the same method as
used for preparation of 2c. Puri¢cation by silica gel £ash column
chromatography (eluent: hexane/AcOEt, 3:1) gave 9c (91%). 9c :
colorless needles (CH2Cl2^hexane); mp 140^141‡C; 1H NMR
(CDCl3) N 1.50^3.80 (10 H, br m), 1.91 (1 H, t, J = 7.2 Hz),
3.87 (2 H, d, J = 7.2 Hz), 4.90 (1 H, s), 6.76 (1 H, ddd, J = 0.9,
2.2, 8.0 Hz), 6.91 (1 H, t, J = 2.2 Hz), 6.99 (1 H, ddd, J = 0.9, 2.2,
8.0 Hz), 7.11 (1 H, t, J = 8.0 Hz). Anal. calcd for C9H18B10O2 : C,
40.59; H, 6.81. Found C, 40.33; H, 6.81.
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5.1.30. 1-Hydroxyethyl-7-(3-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (9d)
Compound 15d was prepared from 15a by the same method as
used for preparation of 4d (52%). 15d : colorless solid; 1H NMR
(CDCl3) N 1.40 (1 H, t, J = 5.4 Hz), 1.50^3.60 (10 H, br m), 2.28
(2 H, t, J = 6.9 Hz), 3.67 (2 H, dt, J = 5.4, 6.9 Hz), 3.79 (3 H, s),
6.82 (1 H, dd, J = 2.2, 8.1 Hz), 6.95 (1 H, s), 7.00 (1 H, br d,
J = 8.1 Hz), 7.16 (1 H, t, J = 8.1 Hz). Compound 9d was prepared
from 15d by the same method as used for preparation of 2d.
Puri¢cation by silica gel £ash column chromatography (eluent:
hexane/AcOEt, 3:1) gave 15d (100%). 15d : colorless needles
(CH2Cl2^hexane); mp 126^127‡C; 1H NMR (CDCl3) N 1.42 (1
H, t, J = 5.5 Hz), 1.30^3.60 (10 H, br m), 2.28 (2 H, t, J = 6.5 Hz)
3.68 (2 H, dt, J = 5.5, 6.5 Hz), 4.84 (1 H, s), 6.75 (1 H, ddd,
J = 0.9, 2.1, 7.9 Hz), 6.89 (1 H, t, J = 2.1 Hz), 6.98 (1 H, ddd,
J = 0.9, 2.1, 7.9 Hz), 7.11 (1 H, t, J = 7.9 Hz). Anal. calcd for
C10H20B10O2 : C, 42.84; H, 7.19. Found C, 42.65; H, 6.90.
5.1.31. 1-Hydroxypropyl-7-(3-hydroxyphenyl)-1,7-dicarba-closo-
dodecaborane (9e)
Compound 15e was prepared from 15a by the same method as
used for preparation of 4e (84%). 15e : colorless solid; 1H NMR
(CDCl3) N 1.24 (1 H, t, J = 5.0 Hz), 1.50^3.50 (10 H, br m), 1.67
(2 H, m), 2.11 (2 H, m), 3.60 (2 H, dt, J = 5.0, 6.0 Hz), 3.79 (3 H,
s), 6.82 (1 H, dd, J = 2.4, 8.2 Hz), 6.96 (1 H, t, J = 2.4 H), 7.00 (1
H, br d, J = 8.2 Hz), 7.16 (1 H, t, J = 8.2 Hz). Compound 9e was
prepared from 15e by the same method as used for preparation of
2e. Puri¢cation by silica gel £ash column chromatography (elu-
ent: hexane/AcOEt, 3:1) gave 9e (90%). 9b : colorless needles
(CH2Cl2^hexane); mp 106^107‡C; 1H NMR (CDCl3) N 1.26 (1
H, t, J = 5.1 Hz), 1.50^3.70 (10 H, br m), 1.67 (2 H, m), 2.11 (2 H,
m), 3.60 (2 H, dt, J = 5.1, 5.6 Hz), 4.87 (1 H, s), 6.75 (1 H, ddd,
J = 0.7, 2.1, 8.1 Hz), 6.90 (1 H, t, J = 2.1 Hz), 6.98 (1 H, ddd,
J = 0.7, 2.1, 8.1 Hz), 7.11 (1 H, t, J = 8.1 Hz). Anal. calcd for
C11H22B10O2 : C, 44.88; H, 7.53. Found C, 44.58; H, 7.35.
5.2. Transfection and luciferase assays
The ER expression plasmid, pCI-rERK, was constructed by
inserting the rat uterus ER cDNA (pUCER6, which was obtained
from the Health Science Research Resources Bank, Osaka, Ja-
pan) into the expression vector pCI-neo (Promega). The reporter
plasmid, EREx5-pGL-TK, was constructed by introducing ¢ve
copies of the estrogen response element (ERE), caAGGTCAcccT-
GACCTcc, and the herpes simplex virus thymidine kinase pro-
moter into the NheI^HindIII sites of the pGL3-Basic luciferase
reporter vector (Promega). The COS-1 cells were obtained from
the Japanese Cancer Research Resources Bank (JCRB) and were
maintained in Dulbecco’s modi¢ed essential medium (DMEM),
supplemented with 5% fetal bovine serum (FBS). For the reporter
gene assay, COS-1 cells were seeded in 24-well tissue culture
plates at 6U104 cells per well with 5% charcoal-stripped FBS/
Fig. 10. Synthetic route used for the preparation of the estrogen ligands bearing carborane (9). Key: (a) (1) n-BuLi, CuCl/DME, (2) m-iodoanisole/pyri-
dine, re£ux; (b) BBr3/CH2Cl2 ; (c) (1) n-BuLi/benzene^Et2O, (2) ClCOOCH3 ; (d) LiAlH4/THF; (e) (1) n-BuLi/benzene^Et2O, (2) (C6H5COO)2/benzene^
Et2O; (f) (1) n-BuLi/benzene^Et2O, (2) Br(CH2)nOTHP; (g) p-TsOHWH2O/MeOH.
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DMEM without phenol red. The cells were cultured at 37‡C in
5% CO2 overnight and allowed to attach to the plates. Then, the
medium was removed and the transfection was performed with
the cationic lipid transfection reagent Tfx-20 (Promega). Lipo-
somes were formed by incubating 100 ng of pCI-rERK, 50 ng
of EREx5-pGL-TK, and 100 ng of the reference plasmid pCMVL
(Clontech) with 0.75 Wl of Tfx-20 in phenol red-free DMEM
(¢nal 200 Wl) for 10^15 min at room temperature. These DNA/
Tfx-20 mixtures were added to the cells and the culture plates
were returned to the CO2 incubator. After 2 h, 800 Wl of DMEM
supplemented with charcoal-stripped FBS (¢nal 0.5%) and 5 Wl of
ethanol solution of ligands were added. After an additional 18 h
of incubation, the cells were harvested, and the luciferase assay
was performed with the Luciferase Assay System (Promega). The
luciferase activities were normalized to L-galactosidase activities.
Each condition was assayed in triplicate.
5.3. ERK ligand-binding assays
The ligand-binding activity of ERK was determined by the
nitrocellulose ¢lter binding assay method. ERK (0.5 Wg/tube, Pan-
Vera Co. Ltd.) was diluted with a binding assay bu¡er (20 mM
Tris^HCl pH 8.0, 0.3 M NaCl, 1 mM EDTA pH 8.0, 10 mM
2-mercaptoethanol, 0.2 mM phenylmethylsulfonyl £uoride) and
incubated with 4 nM [6,7-3H]17L-estradiol in the presence or
absence of an unlabeled competitor at 4‡C for 16 h. The incuba-
tion mixture was absorbed by suction onto a nitrocellulose mem-
brane that had been soaked in binding assay bu¡er. The mem-
brane was washed twice with bu¡er (20 mM Tris^HCl pH 8.0, 0.3
M NaCl) and then with 25% ethanol in distilled water. Radio-
activity that remained on the membrane was measured in Atom-
light (NEN) using a liquid scintillation counter.
5.4. Animal studies
Eight-week-old female mice of the ddy strain were obtained
from Japan SLC Inc. (Shizuoka, Japan). Mice were either
sham-operated or OVX, and some of the OVX mice were sub-
cutaneously administered either 1^100 ng/day of 2c or 100 ng/day
of 17L-estradiol (1) dissolved in polyethyleneglycol 300 using a
miniosmotic pump (Alza Co.), immediately after the surgery. At
4 weeks after the surgery, the mice were killed and the weight of
the uterus was measured, and the right and left femurs were
removed to measure BMD.
5.5. Radiographic analysis of the femur
Radiographic photographs of the femurs were taken with soft
X-rays (model CMB-2, SOFTEX). The BMD of the femurs was
measured by dual X-ray absorptiometry (model DCS-600R, Alo-
ka). The bone mineral content (BMC) of the mouse femur was
correlated closely with the ash weight. BMD was calculated by
dividing BMC of the measured area by the area. The scanned
area was divided into three parts: proximal femur, midshaft, and
distal femur.
5.6. Docking simulation
The most stable docking models for all compounds were esti-
mated using the automatic docking program ADAM version 4.11
[34]. Energy minimization of the docking models was done by the
SANDER module of the AMBER 5 program package. Energy
decomposition analyses of the ¢nal docking models were done by
the ANAL module of AMBER 5 [37]. The structure of the hu-
man ERKLBD was obtained from the crystal structure of the
ERKLBD complex (PDB code 1ERE A-chain) by removing the
17L-estradiol molecule. All hydrogen atoms that are missing in
the crystal structure but should exist in the protein structure were
computationally located at appropriate positions and optimized
further by the AMBER program.
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